Lifevantage (LFVN) Stock Price, News & Analysis

Company Overview

LifeVantage Corporation (NASDAQ: LFVN) is a science-based nutraceutical company that develops and distributes dietary supplements, personal care products and wellness solutions. Founded in 2003, LifeVantage operates through a direct-to-consumer, multi-level marketing model, leveraging a network of independent distributors to market its core offerings, including the Protandim® line of cellular health supplements and the TrueScience® skin care collection. The company’s research and development efforts focus on harnessing the power of nutrigenomics and antioxidative support to promote long-term health and well-being.

LifeVantage’s flagship Protandim® NRF1 Synergizer™ and Protandim® NRF2 Synergizer™ products are formulated to target cellular homeostasis by activating key pathways associated with oxidative stress and mitochondrial function. In parallel, the TrueScience® skin care range features anti-aging serums, cleansers and moisturizers designed to support skin health through peptide technology and botanical extracts. The company periodically introduces new products following internal clinical studies and third-party testing to validate efficacy and safety.

Since its incorporation, LifeVantage has expanded its geographic footprint to serve customers across North America, Europe, the Asia-Pacific region and select markets in Latin America. The company maintains corporate offices in Sandy, Utah, and field operations in major international hubs, with dedicated teams managing regulatory compliance, distribution logistics and distributor training in each region. This global presence allows LifeVantage to adapt its product portfolio to local regulations and consumer preferences while fostering cross-border collaboration among its distributor community.

Leadership at LifeVantage includes Chief Executive Officer Darren E. Jensen, who joined the company in 2017 and brings extensive experience in consumer products and direct sales. Jensen is supported by a management team with backgrounds in biotechnology, regulatory affairs and supply chain management. Under their direction, LifeVantage continues to emphasize scientific validation, quality manufacturing practices and distributor education as pillars of its growth strategy, aiming to strengthen its position in the competitive wellness and anti-aging market.

Key Stats

• Today's Range: $13.02 to $14.17
• 50-Day Range: $11.18 to $14.12
• 52-Week Range: $5.52 to $27.38
• Volume: 149,005 shs
• Average Volume: 156,078 shs
• Market Capitalization: $164.43 million
• P/E Ratio: 18.93
• Dividend Yield: 1.38%
• Price Target: $30.50
• Consensus Rating: Buy

Lifevantage Stock Analysis - MarketRank™

Lifevantage scored higher than 86% of companies evaluated by MarketBeat, and ranked 150th out of 920 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 3.5 / 5
• Analyst Rating: Buy

Consensus Rating

Lifevantage has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 2 buy ratings, no hold ratings, and no sell ratings.

Amount of Analyst Coverage

Lifevantage has received no research coverage in the past 90 days.

Earnings and Valuation

• Score: 1.3 / 5
• Proj. Earnings Growth: N/A

Price to Earnings Ratio vs. the Market

The P/E ratio of Lifevantage is 18.93, which means that it is trading at a less expensive P/E ratio than the market average P/E ratio of about 25.92.

Price to Earnings Ratio vs. Sector

The P/E ratio of Lifevantage is 18.93, which means that it is trading at a less expensive P/E ratio than the Medical sector average P/E ratio of about 28.01.

Price to Book Value per Share Ratio

Lifevantage has a P/B Ratio of 6.37. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

Short Interest

• Score: 0.0 / 5
• Short Interest Level: Bearish

Percentage of Shares Shorted

20.38% of the float of Lifevantage has been sold short.

Short Interest Ratio / Days to Cover

Lifevantage has a short interest ratio ("days to cover") of 12.6, which indicates bearish sentiment.

Change versus previous month

Short interest in Lifevantage has recently increased by 3.52%, indicating that investor sentiment is decreasing.

Dividend

• Score: 1.7 / 5
• Dividend Strength: Weak

Dividend Yield

Lifevantage pays a meaningful dividend of 1.27%, higher than the bottom 25% of all stocks that pay dividends.

Dividend Growth

Lifevantage has only been increasing its dividend for 3 years.

Dividend Coverage

The dividend payout ratio of Lifevantage is 26.09%. This payout ratio is at a healthy, sustainable level, below 75%.

Sustainability and ESG

• Score: 2.7 / 5
• Environmental Score: -1.50

Percentage of Shares Shorted

20.38% of the float of Lifevantage has been sold short.

Short Interest Ratio / Days to Cover

Lifevantage has a short interest ratio ("days to cover") of 12.6, which indicates bearish sentiment.

Change versus previous month

Short interest in Lifevantage has recently increased by 3.52%, indicating that investor sentiment is decreasing.

News and Social Media

• Score: 3.3 / 5
• News Sentiment: 0.88

News Sentiment

Lifevantage has a news sentiment score of 0.88. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.56 average news sentiment score of Medical companies.

News Coverage This Week

MarketBeat has tracked 3 news articles for Lifevantage this week, compared to 3 articles on an average week.

Search Interest

2 people have searched for LFVN on MarketBeat in the last 30 days. This is an increase of 100% compared to the previous 30 days.

MarketBeat Follows

1 people have added Lifevantage to their MarketBeat watchlist in the last 30 days.

Company Ownership

• Score: 2.5 / 5
• Insider Trading: Selling Shares

Insider Buying vs. Insider Selling

In the past three months, Lifevantage insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $36,769.00 in company stock.

Percentage Held by Insiders

20.65% of the stock of Lifevantage is held by insiders. A high percentage of insider ownership can be a sign of company health.

Percentage Held by Institutions

Only 35.32% of the stock of Lifevantage is held by institutions.

LFVN Stock Analysis - Frequently Asked Questions

How have LFVN shares performed this year?

Lifevantage's stock was trading at $17.53 at the beginning of 2025. Since then, LFVN stock has decreased by 25.5% and is now trading at $13.06.

How were Lifevantage's earnings last quarter?

Lifevantage Corporation (NASDAQ:LFVN) announced its quarterly earnings data on Tuesday, May, 6th. The company reported $0.26 earnings per share for the quarter, topping the consensus estimate of $0.16 by $0.10. The business earned $58.44 million during the quarter, compared to analysts' expectations of $60.99 million. Lifevantage had a net margin of 4.12% and a trailing twelve-month return on equity of 34.67%.
Read the conference call transcript.

How do I buy shares of Lifevantage?

Shares of LFVN stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

What other stocks do shareholders of Lifevantage own?

Based on aggregate information from My MarketBeat watchlists, some other companies that Lifevantage investors own include Humana (HUM), American Water Works (AWK), Waste Connections (WCN), Voyager Therapeutics (VYGR), The RMR Group (RMR), DiamondRock Hospitality (DRH) and iShares Micro-Cap ETF (IWC).

Company Calendar

• Last Earnings: 5/06/2025
• Record date for 6/13 Dividend: 5/30/2025
• Ex-Dividend for 6/13 Dividend: 5/30/2025
• Dividend Payable: 6/13/2025
• Today: 7/10/2025
• Next Earnings (Estimated): 8/27/2025
• Fiscal Year End: 6/30/2026

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: MED/DENTAL - SUPP
• Sub-Industry: Pharmaceutical Products
• Current Symbol: NASDAQ:LFVN
• CIK: 849146
• Web: www.lifevantage.com
• Phone: (801) 432-9000
• Fax: 801-880-0699
• Employees: 260
• Year Founded: N/A

Price Target and Rating

• Average Price Target for Lifevantage: $30.50
• High Price Target: $35.00
• Low Price Target: $26.00
• Potential Upside/Downside: +133.5%
• Consensus Rating: Buy
• Rating Score (0-4): 3.00
• Research Coverage: 2 Analysts

Profitability

• EPS (Trailing Twelve Months): $0.69
• Trailing P/E Ratio: 18.93
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: $2.94 million
• Net Margins: 4.12%
• Pretax Margin: 5.65%
• Return on Equity: 34.67%
• Return on Assets: 15.24%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 1.66
• Quick Ratio: 0.98

Sales & Book Value

• Annual Sales: $200.16 million
• Price / Sales: 0.82
• Cash Flow: $0.82 per share
• Price / Cash Flow: 16.01
• Book Value: $2.05 per share
• Price / Book: 6.37

Miscellaneous

• Outstanding Shares: 12,590,000
• Free Float: 9,989,000
• Market Cap: $164.43 million
• Optionable: Optionable
• Beta: 0.43